GenomeDx Decipher Bladder Cancer Classifier
GenomeDx Biosciences launched its Decipher Bladder Cancer Classifier, a clinical assay for subtyping muscle invasive bladder cancer. The commercial launch follows the publication of a study supporting the assay's development and validation. The test is for use by physicians to stratify patients into more accurate risk groups than can be done with traditional diagnostic diagnostic tools. It also is for identifying those patients who are most likely to benefit from additional treatment.